Development and evaluation of ultrasound contrast agents with AS1411-conjugated nanoparticles with liquid core.
10.11817/j.issn.1672-7347.2018.06.006
- Author:
Zheng WANG
1
;
Jingsong DING
2
;
Shengjuan LUO
3
;
Peiqi WANG
4
;
Qi LIANG
5
Author Information
1. Department of Hepatobiliary Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China.
2. Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China.
3. Department of Ultrasound, Third Xiangya Hospital, Central South University, Changsha 410013, China.
4. Department of Pharmacy, Cancer Hospital of Henan Province, Zhengzhou 450008, China.
5. Department of Radiology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
- Publication Type:Journal Article
- MeSH:
Cell Survival;
Contrast Media;
chemical synthesis;
Fluorocarbons;
Humans;
MCF-7 Cells;
Microscopy, Electron, Scanning Transmission;
Nanoparticles;
chemistry;
ultrastructure;
Oligodeoxyribonucleotides;
chemical synthesis
- From:
Journal of Central South University(Medical Sciences)
2018;43(6):610-618
- CountryChina
- Language:Chinese
-
Abstract:
To prepare AS1411 targeted nano-ultrasonic contrast agent with liquid core, and to evaluate its ability for ultrasonic contrast enhancement and targeting MCF-7 cell in vitro.
Methods: The modified solvent evaporation, self-synthesized membrane material and perfluorobrominane (PFOB) was used to form nano-ultrasonic contrast agent with PFOB core (nanoparticles, NP); then N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS) catalysis was used to connect AS1411 to the surface of NP to prepare NP-AS1411. The transmission electron microscopy was chosen to check the morphology of NP-AS1411. The size, surface charge, encapsulation efficiency, biocompatibility, the contrast grey value and the stability of NP-AS1411 and NP were compared. Whether AS411 was attached to the surface of NP was checked by gel electrophoresis. Fluorescence microscopy and flow cytometry were performed to examine the targeting ability of AS1411.
Results: NP-AS1411 was a shell-nuclear structure under the electron microscope. Its size was at (245.4±16.5) nm, which was larger than that of NP (P=0.05). There was no significant difference in surface charge and encapsulation efficiency between NP-AS1411 and NP (P>0.05). In the MTT experiment, the cell viability decreased significantly at high concentration of NP-AS411 (25 mg/mL) after incubation for 24 h compared with the control group (0 mg/mL ) (P<0.05). The contrast gray value of NP-AS1411 was at 86.1+ 6.7, which was significantly higher than that of deionized water (P<0.05), and equivalent to that of NP (P>0.05). The contrast grey value of AS1411-NP was 80.1±9.2 after keeping at room temperature for 24 h, which showed no obviously change comparing with that before the treatment (P>0.05). The size of NP-AS1411didn't change too (P>0.05). The results of gel electrophoresis demonstrated that the AS1411 connecting to the surface of NP was the most when the molar ratio of NP:AS1411 was at 40:1. Flow cytometry analysis confirmed that NP and NP-AS1411 were combined with MCF-7 cells separately but the fluorescence produced by the combination of NP-AS1411 and MCF-7 was more intense.
Conclusion: The modified solvent evaporation and EDC/NHS catalysis could successfully prepare ultrasound contrast agents with aptamer-conjugated nanoparticles with liquid core. The targeted ultrasonic contrast agents with liquid core possess good ultrasonic contrast enhancement ability in vitro, stability and specificity as well.
